Ligand Pharmaceuticals said it has reached a deal to acquire Xoma Royalty, a company that invests in a range of biotech firms, for around $740 million

Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.

Discover more from RealUS.news

Subscribe now to keep reading and get access to the full archive.

Continue reading